Liquid biopsy in metastatic breast cancer

Abstract

The spread of single tumor cells shed by the primary tumor has been observed in most solid carcinomas and is generally associated with poor clinical outcome. Tumor cells detected in the peripheral blood are commonly referred to as circulating tumor cells (CTCs) and are seen as possible precursors of metastatic disease. Beyond CTCs, circulating tumor DNA and non-coding RNA are increasingly the focus of translation cancer research. In metastatic breast cancer (MBC), elevated levels of CTCs have been confirmed as an independent prognostic factor. While detection of elevated counts after the start of systemic therapy predicts poor response, it is unclear which treatment strategy should be offered in the case of CTC persistence. Currently, the main potentials of blood-based diagnostics in BC are therapy monitoring and liquid biopsy-based treatment interventions. Recently, the first positive study on CTC-guided therapy choices in hormone receptor positive HER2 negative MBC was published. In the present review, we discuss the current data and potential clinical application of liquid biopsy in the metastatic setting.

Keywords

Tumor cell dissemination / circulating tumor cell / liquid biopsy / circulating tumor DNA / breast cancer

References

[1] Ashworth TR.A case of cancer in which cells similar to those in tumors were seen in the blood after death..Aus Med J1869;14:146-9

[2] Banys M,Gruber I,Wallwiener M.Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situ..Breast Cancer Res Treat2014;144:531-8

[3] Husemann Y,Schubert F,Meyer M.Systemic spread is an early step in breast cancer..Cancer Cell2008;13:58-68

[4] Braun S,Naume B,Osborne MP.A pooled analysis of bone marrow micrometastasis in breast cancer..N Engl J Med2005;353:793-802

[5] Janni WJ,Terstappen LW,Taran FA.Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer..Clin Cancer Res2016;22:2583-93

[6] Sparano JA,Alpaugh K,Northfelt DW.Abstract GS6-03: circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer..SABCS2018;78:

[7] Sparano J,Alpaugh K,Northfelt DW.Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial..JAMA Oncol2018;4:1700-6 PMCID:PMC6385891

[8] Janni W,Fasching P,Tesch H.Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: results from the adjuvant SUCCESS A trial..J Clin Oncol2018;36:

[9] Cristofanilli M,Ellis MJ,Matera J.Circulating tumor cells, disease progression, and survival in metastatic breast cancer..N Engl J Med2004;351:781-91

[10] Riethdorf S,Müller V,Schindlbeck C.Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cellsearch system..Clin Cancer Res2007;13:920-8

[11] Banys-Paluchowski M,Meier-Stiegen F,Solomayer EF.Circulating and disseminated tumour cells in breast carcinoma: report from the consensus conference on tumour cell dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018..Geburtshilfe Frauenheilkd2019;79:177-83 PMCID:PMC6379163

[12] Cristofanilli M,Reuben J,Davis AA.The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): international expert consensus paper..Crit Rev Oncol Hematol2019;134:39-45

[13] Giordano A,De Laurentiis M,Jackson S.Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy..Ann Oncol2012;23:1144-50

[14] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy..Cancer Res1977;37:646-50

[15] Diaz LA Jr.Liquid biopsies: genotyping circulating tumor DNA..J Clin Oncol2014;32:579-86 PMCID:PMC4820760

[16] Diehl F,Choti MA,Goodman S.Circulating mutant DNA to assess tumor dynamics..Nat Med2008;14:985-90 PMCID:PMC2820391

[17] Bettegowda C,Leary RJ,Wang Y.Detection of circulating tumor DNA in early- and late-stage human malignancies..Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[18] Tan G,Gui X,Chen Q.The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis..Medicine (Baltimore)2018;97:e0197 PMCID:PMC5895387

[19] Smerage JB,Hortobagyi GN,Leyland-Jones B.Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500..J Clin Oncol2014;32:3483-9 PMCID:PMC4209100

[20] Dawson SJ,Caldas C.Circulating tumor DNA to monitor metastatic breast cancer..N Engl J Med2013;369:93-4

[21] Andre F,Rubovszky G,Loibl S.Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer..N Engl J Med2019;380:1929-40

[22] Juric D,Rubovszky G,Loibl S.Abstract GS3-08: alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial..Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR;2019;

[23] Turner N,Kilburn L,Johnston S.Abstract PD2-04: baseline circulating ESR1 mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer..Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR;2019;

[24] O’Leary B,Liu Y,Huang X.The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial..Cancer Discov2018;8:1390-403 PMCID:PMC6368247

[25] Stover DG,Ha G,Barry WT.Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer..J Clin Oncol2018;36:543-53 PMCID:PMC5815405

[26] Bidard FC,Dureau S,Bachelot T.Abstract GS3-07: clinical utility of circulating tumor cell count a s a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: results of the phase III STIC CTC trial..Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR;2019;

[27] Huober J,Taran FA,Overkamp F.Abstract P3-11-07: factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer - data from the PRAEGNANT breast cancer registry..Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR;2018;

[28] Banys M,Becker S,Staebler A.The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer..Breast Cancer Res Treat2012;132:121-9

[29] Pantel K.Dissecting the metastatic cascade..Nat Rev Cancer2004;4:448-56

[30] Klein CA.Parallel progression of primary tumours and metastases..Nat Rev Cancer2009;9:302-12